NurExone Biologic (J90) Stock Price & Analysis

J90 Stock Chart & Stats

€0.29-€0.01(-2.00%)

At close: Oct 30 1:00 AM GMT+1

Day’s Range: EUR 0.29 - EUR 0.31
52-Week Range: EUR 0.24 - EUR 0.48
Previous Close: EUR 0.30
Volume: N/A
Average Volume (3M): 509
Market Cap: EUR 23.84M
Enterprise Value: EUR 49.36M
Total Cash (Recent Filing): EUR 1.01M
Total Debt (Recent Filing): EUR 52.00K
Price to Earnings (P/E): ―
Beta: -0.16
Next Earnings: Nov 20, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

CNS Exosome Platform And Pipeline

A focused CNS pipeline built around an exosome delivery platform gives NurExone a coherent development strategy across related neurological indications. If research advances, the shared platform could support multiple assets and create opportunities for partnerships or licensing over time.

Low Financial Leverage

Very low leverage limits interest obligations and reduces balance-sheet pressure while the company funds development. Compared with a highly indebted biotech, this provides greater flexibility to direct capital toward research and preserves capacity to raise funding without first addressing substantial debt commitments.

Losses Broadly Reflect Operating Cash Burn

The close relationship between reported net loss and free-cash-flow consumption gives a clearer view of the company’s underlying operating economics. Although cash generation is weak, this alignment reduces the risk that headline results obscure additional cash demands from non-cash accounting effects.

Bears Say

No Reported Commercial Revenue

Zero revenue means the business has not yet established a commercial income stream to support research, administration, or future trials. Until a candidate reaches commercialization or a monetizing partnership is secured, valuation depends heavily on development execution and continued access to external capital.

Persistent Operating Losses

Continuing sizable losses show that the current operating model is consuming resources without producing earnings or visible profitability. Persistent deficits can constrain investment choices, increase dependence on financing, and make progress toward a self-sustaining business dependent on successful clinical and regulatory development.

Sustained Cash Burn And Shrinking Equity

Ongoing operating and free-cash-flow deficits create a durable funding requirement as development continues. The decline in equity alongside cash burn indicates that the balance sheet is being consumed to fund operations, increasing exposure to future financing needs and potential dilution if losses persist.

NurExone Biologic News

NurExone Shows Consistent Anti-Inflammatory Activity in Naïve Exosome Batches

The latest announcement is out from NurExone Biologic ( ($TSE:NRX) ). NurExone Biologic reported new laboratory data showing that three separately manufactured batches of its bone marrow-derived naïve exosomes exhibit

4d agoJ90 NRX

NurExone Doubles Exosome Output With Parallel Bioreactors, Advancing Modular Manufacturing Strategy

NurExone Biologic ( ($TSE:NRX) ) has issued an announcement. NurExone Biologic has demonstrated that operating two bioreactors in parallel can double exosome yield while maintaining production time and key quality

1w agoJ90 NRX

NurExone Advances Exosome Therapy After Positive Optic Nerve Data

NurExone Biologic ( ($TSE:NRX) ) has shared an announcement. NurExone reported new preclinical data from an optic nerve crush study in rats conducted with Sheba Medical Center, showing that both

3w agoJ90 NRX

NurExone Steps Up U.S. Push With Boston Life Sciences Events and Investor Campaign

An update from NurExone Biologic ( ($TSE:NRX) ) is now available. NurExone Biologic is intensifying its U.S. presence as it advances exosome-based regenerative therapies, including its lead candidate ExoPTEN for

1M agoJ90 NRX

NurExone Shareholders Back Board, Clear Path for Potential 30-for-1 Share Consolidation

An announcement from NurExone Biologic ( ($TSE:NRX) ) is now available. NurExone Biologic reported that shareholders overwhelmingly approved all resolutions at its annual general and special meeting, including the re-election

1M agoJ90 NRX

NurExone advances exosome programs as R&D spend rises and new financing secured

NurExone Biologic ( ($TSE:NRX) ) has provided an announcement. NurExone reported second-quarter 2026 results showing higher research and development spending of US$0.75 million, driven by advancement of its ExoPTEN program,

2M agoJ90 NRX

NurExone to Spotlight Exosome Platform at Moody Capital Disruptive Growth Conference

NurExone Biologic ( ($TSE:NRX) ) has provided an announcement. NurExone Biologic Inc. will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York, where

2M agoJ90 NRX

NurExone Seeks Shareholder Approval for Share Consolidation to Support U.S. Listing Bid

NurExone Biologic ( ($TSE:NRX) ) has provided an update. NurExone Biologic has called an annual general and special meeting for September 15, 2026, where shareholders will vote on a proposed

2M agoJ90 NRX

NurExone Raises C$1.07 Million in Private Placement to Support Regenerative Therapy Push

NurExone Biologic ( ($TSE:NRX) ) has provided an announcement. NurExone Biologic has closed a non-brokered private placement of 1,938,326 units at C$0.55 per unit, raising approximately C$1.07 million in gross

2M agoJ90 NRX

NurExone Preclinical Data Bolster Neuroprotective Case for ExoPTEN in Spinal Cord Injury

NurExone Biologic ( ($TSE:NRX) ) has issued an update. NurExone Biologic reported new preclinical tissue-analysis data indicating that animals treated with its exosome-based candidate ExoPTEN showed significantly higher numbers of

2M agoJ90 NRX

J90 FAQ

What was NurExone Biologic’s price range in the past 12 months?

NurExone Biologic lowest stock price was €0.24 and its highest was €0.48 in the past 12 months.

What is NurExone Biologic’s market cap?

NurExone Biologic’s market cap is €23.84M.

When is NurExone Biologic’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were NurExone Biologic’s earnings last quarter?

NurExone Biologic released its earnings results on Aug 31, 2026. The company reported €0.018 earnings per share for the quarter, beating the consensus estimate of -€0.018 by €0.036.

Is NurExone Biologic overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does NurExone Biologic pay dividends?

NurExone Biologic does not currently pay dividends.

What is NurExone Biologic’s EPS estimate?

NurExone Biologic’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NurExone Biologic have?

NurExone Biologic has 77,746,750 shares outstanding.

What happened to NurExone Biologic’s price movement after its last earnings report?

NurExone Biologic reported an EPS of €0.018 in its last earnings report, beating expectations of -€0.018. Following the earnings report the stock price went up 0.909%.

Which hedge fund is a major shareholder of NurExone Biologic?

Currently, no hedge funds are holding shares in DE:J90

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description